Wang-Chesebro Alice, Xia Ping, Coleman Joy, Akazawa Clayton, Roach Mack
Department of Radiation Oncology, University of California-San Francisco, San Francisco, CA 94115, USA.
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):654-62. doi: 10.1016/j.ijrobp.2006.05.037.
The aim of this study was to quantify gains in lymph node coverage and critical structure dose reduction for whole-pelvis (WP) and extended-field (EF) radiotherapy in prostate cancer using intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3DCRT) for the first treatment phase of 45 Gy in the concurrent treatment of lymph nodes and prostate.
From January to August 2005, 35 patients with localized prostate cancer were treated with pelvic IMRT; 7 had nodes defined up to L5-S1 (Group 1), and 28 had nodes defined above L5-S1 (Group 2). Each patient had 2 plans retrospectively generated: 1 WP 3DCRT plan using bony landmarks, and 1 EF 3DCRT plan to cover the vascular defined volumes. Dose-volume histograms for the lymph nodes, rectum, bladder, small bowel, and penile bulb were compared by group.
For Group 1, WP 3DCRT missed 25% of pelvic nodes with the prescribed dose 45 Gy and missed 18% with the 95% prescribed dose 42.75 Gy, whereas WP IMRT achieved V(45 Gy) = 98% and V(42.75 Gy) = 100%. Compared with WP 3DCRT, IMRT reduced bladder V(45 Gy) by 78%, rectum V(45 Gy) by 48%, and small bowel V(45 Gy) by 232 cm3. EF 3DCRT achieved 95% coverage of nodes for all patients at high cost to critical structures. For Group 2, IMRT decreased bladder V(45 Gy) by 90%, rectum V(45 Gy) by 54% and small bowel V(45 Gy) by 455 cm3 compared with EF 3DCRT.
In this study WP 3DCRT missed a significant percentage of pelvic nodes. Although EF 3DCRT achieved 95% pelvic nodal coverage, it increased critical structure doses. IMRT improved pelvic nodal coverage while decreasing dose to bladder, rectum, small bowel, and penile bulb. For patients with extended node involvement, IMRT especially decreases small bowel dose.
本研究的目的是量化在前列腺癌全盆腔(WP)和扩大野(EF)放疗中,与三维适形放疗(3DCRT)相比,调强放疗(IMRT)在淋巴结覆盖范围增加和关键结构剂量降低方面的效果,用于在同时治疗淋巴结和前列腺的第一阶段给予45 Gy剂量时。
2005年1月至8月,35例局限性前列腺癌患者接受盆腔IMRT治疗;7例患者的淋巴结定义至L5-S1(第1组),28例患者的淋巴结定义在L5-S1以上(第2组)。每位患者均回顾性生成2个计划:1个使用骨性标志的WP 3DCRT计划,以及1个覆盖血管定义体积的EF 3DCRT计划。按组比较淋巴结、直肠、膀胱、小肠和阴茎球部的剂量体积直方图。
对于第1组,WP 3DCRT在规定剂量45 Gy时遗漏25%的盆腔淋巴结,在95%规定剂量42.75 Gy时遗漏18%,而WP IMRT实现V(45 Gy)=98%和V(42.75 Gy)=100%。与WP 3DCRT相比,IMRT使膀胱V(45 Gy)降低78%,直肠V(45 Gy)降低48%,小肠V(45 Gy)降低232 cm³。EF 3DCRT以对关键结构造成高代价为前提,实现了所有患者95%的淋巴结覆盖。对于第2组,与EF 3DCRT相比,IMRT使膀胱V(45 Gy)降低90%,直肠V(45 Gy)降低54%,小肠V(45 Gy)降低455 cm³。
在本研究中,WP 3DCRT遗漏了相当比例的盆腔淋巴结。虽然EF 3DCRT实现了95%的盆腔淋巴结覆盖,但增加了关键结构的剂量。IMRT改善了盆腔淋巴结覆盖,同时降低了膀胱、直肠、小肠和阴茎球部的剂量。对于有广泛淋巴结受累的患者,IMRT尤其降低了小肠剂量。